Relapsing Multiple SclerosisPhase 3NCT04338061
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
A Phase 3 study testing Teriflunomide and Evobrutinib in people with Relapsing Multiple Sclerosis, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany at 278 sites in 32 countries.
Trial summary
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Read more about this study
- Who is it for?
- Ages 18 to 55 years
- Conditions the study is for
- Relapsing Multiple Sclerosis
- What is being tested?
- Teriflunomide and Evobrutinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,166 participants
- Where
- 278 sitesin 32 countries
- Study dates
- 2 Jul 2020to 19 Mar 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
- Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
- Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score less than or equal to [<=] 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
- Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
- Female participants must be neither pregnant nor breast-feeding or must lack child-bearing potential (as defined by either: post-menopausal or surgically sterile), or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
- Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
- Participants have given written informed consent prior to any study-related procedure
- Other protocol defined inclusion criteria could apply.
Who cannot join
- Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b) Participants with secondary progressive MS without evidence of relapse
- Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at screening and Baseline (Day 1)
- Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV), intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
- Other protocol defined exclusion criteria could apply.
Trial locations and contacts
278 sites in 32 countries.
278 sites in 32 countries
United States38 sites
Research Site 746
Altamonte Springs, Florida, 32714
Research Site 724
Amherst, New York, 14226
Research Site 736
Asheville, North Carolina, 28006
Research Site 711
Canton, Ohio, 44735
Research Site 712
Chapel Hill, North Carolina, 27599
Research Site 759
Colorado Springs, Colorado, 80907
Research Site 757
Columbus, Ohio, 43214
Research Site 752
Cullman, Alabama, 35058
Research Site 734
Dayton, Ohio, 45459
Research Site 738
Detroit, Michigan, 48202
Research Site 715
Evanston, Illinois, 60201
Research Site 725
Fort Collins, Colorado, 80528
Research Site 714
Fort Wayne, Indiana, 46804
Research Site 751
Hanford, California, 93230
Research Site 742
Honolulu, Hawaii, 96817
Research Site 718
Jacksonville, Florida, 32209
Research Site 744
Lafayette, Indiana, 47904
Research Site 702
Naples, Florida, 34105
Research Site 735
Nicholasville, Kentucky, 40356
Research Site 721
Norfolk, Virginia, 23502
Research Site 740
Orlando, Florida, 32806
Research Site 717
Overland Park, Kansas, 66212
Research Site 748
Philadelphia, Pennsylvania, 19107
Research Site 726
Port Charlotte, Florida, 33952
Research Site 730
Raleigh, North Carolina, 27607
Research Site 703
San Antonio, Texas, 78258
Research Site 719
Sarasota, Florida, 34243
Research Site 706
Scarborough, Maine, 04074
Research Site 741
Scottsdale, Arizona, 85258
Research Site 723
St Louis, Missouri, 63128
Research Site 743
Tampa, Florida, 33612
Research Site 707
Tampa, Florida, 33634
Research Site 704
Tucson, Arizona, 85710
Research Site 732
Vero Beach, Florida, 32960
Research Site 705
Weeki Wachee, Florida, 34607
Research Site 737
West Hollywood, California, 90048
Research Site 753
West Palm Beach, Florida, 33407
Research Site 728
Winston-Salem, North Carolina, 27157
Russia23 sites
Research Site 325
Kazan'
Research Site 329
Kazan'
Research Site 323
Kemerovo
Research Site 344
Kirov
Research Site 340
Krasnodar
Research Site 334
Krasnoyarsk
Research Site 341
Moscow
Research Site 343
Moscow
Research Site 345
Moscow
Research Site 332
Nizhny Novgorod
Research Site 327
Novosibirsk
Research Site 330
Novosibirsk
Research Site 331
Novosibirsk
Research Site 335
Novosibirsk
Research Site 328
Rostov-on-Don
Research Site 324
Saint Petersburg
Research Site 338
Saint Petersburg
Research Site 339
Saint Petersburg
Research Site 342
Saint Petersburg
Research Site 346
Saint Petersburg
Research Site 326
Saransk
Research Site 321
Sestroretsk
Research Site 337
Tyumen
Ukraine23 sites
Research Site 415
Chernihiv
Research Site 417
Chernihiv
Research Site 414
Dnipro
Research Site 416
Dnipro
Research Site 420
Dnipro
Research Site 413
Ivano-Frankivsk
Research Site 624
Kharkiv
Research Site 632
Kharkiv
Research Site 633
Kharkiv
Research Site 419
Kherson
Research Site 411
Kyiv
Research Site 418
Kyiv
Research Site 629
Lutsk
Research Site 627
Lviv
Research Site 622
Poltava
Research Site 625
Rivne
Research Site 628
Ternopil
Research Site 630
Uzhhorod
Research Site 623
Vinnytsia
Research Site 412
Zaporizhzhya
Research Site 621
Zaporizhzhya
Research Site 631
Zaporizhzhya
Research Site 626
Zhytomyr
Poland19 sites
Reserach Site 267
Bydgoszcz
Reserach Site 268
Bydgoszcz
Research Site 273
Katowice
Research site 846
Katowice
Research site 274
Katowice-Ochojec
Research Site 276
Krakow
Research Site 263
Lodz
Research Site 272
Lodz
Research Site 266
Nowa Sól
Research Site 270
Poznan
Research Site 262
Rzeszów
Research Site 265
Siemianowice Śląskie
Research Site 271
Szczecin
Research Site 264
Warsaw
Research Site 277
Warsaw
Reserach Site 275
Warsaw
Research Site 269
Wroclaw
Research Site 261
Zabrze
Research Site 278
Zamość
Bulgaria16 sites
Research Site 155
Blagoevgrad
Research Site 156
Dupnitsa
Research Site 157
Pleven
Research Site 801
Pleven
Research Site 804
Pleven
Research Site 805
Plovdiv
Research Site 151
Sofia
Research Site 152
Sofia
Research Site 153
Sofia
Research Site 158
Sofia
Research Site 159
Sofia
Research Site 160
Sofia
Research Site 802
Sofia
Research Site 803
Sofia
Research Site 808
Sofia
Research Site 154
Veliko Tarnovo
Greece15 sites
Research Site 194
Athens
Research Site 196
Athens
Research Site 197
Athens
Research Site 201
Athens
Research Site 202
Athens
Research Site 205
Athens
Research Site 207
Athens
Reserach Site 206
Athens
Research Site 198
Heraklion
Research Site 204
Ioannina
Research Site 192
Larissa
Research Site 199
Marousi
Research Site 191
Pátrai
Research Site 203
Pátrai
Research Site 195
Thessaloniki
Germany14 sites
Research Site 172
Augsburg
Research Site 177
Berlin
Research Site 180
Berlin
Research Site 178
Bonn
Research Site 179
Cologne
Research Site 184
Dresden
Research Site 174
Hamburg
Research Site 182
Heidelberg
Research Site 181
Leipzig
Research Site 173
Mainz
Research Site 176
Minden
Research Site 171
Regensburg
Research Site 183
Rostock
Research Site 175
Tübingen
Turkey (Türkiye)13 sites
Research Site 538
Ankara
Research Site 544
Ankara
Research Site 531
Istanbul
Research Site 534
Istanbul
Research Site 536
Istanbul
Research Site 541
Istanbul
Research Site 543
Istanbul
Research Site 539
Izmir
Research Site 533
Kocaeli
Research Site 537
Konya
Research Site 540
Mersin
Research Site 535
Samsun
Research Site 532
Trabzon
Italy12 sites
Research Site 218
Bari
Research Site 216
Catania
Research Site 214
Cefalù
Research Site 219
Florence
Research Site 221
Milan
Research Site 211
Naples
Research Site 215
Naples
Research Site 220
Orbassano
Research Site 217
Palermo
Research Site 212
Pozzilli
Research Site 213
Roma
Research Site 222
Roma
Spain12 sites
Research Site 384
Alcorcón
Research Site 391
Barakaldo
Research Site 390
Barcelona
Research Site 382
Córdoba
Research Site 389
El Palmar
Research Site 388
Madrid
Research Site 392
Majadahonda
Research Site 383
Málaga
Research Site 387
Seville
Research Site 385
Valencia
Research Site 386
Valencia
Research Site 381
Vigo
Portugal11 sites
Research Site 293
Aveiro
Research Site 282
Braga
Research Site 289
Coimbra
Research Site 281
Lisbon
Research Site 283
Lisbon
Research Site 287
Lisbon
Research SIte 284
Matosinhos Municipality
Research Site 292
Porto
Research Site 288
Pragal
Research Site 291
Santa Maria da Feira
Research Site 286
Torres Vedras
Brazil9 sites
Research Site 603
Belo Horizonte
Research Site 599
Curitiba
Research Site 604
Goiânia
Research Site 600
Joinville
Research Site 614
Passo Fundo
Research Site 591
Porto Alegre
Research Site 594
Porto Alegre
Research Site 596
Porto Alegre
Research Site 609
Vitória
France9 sites
Research Site 455
Bordeaux
Research Site 459
Brest
Reserach Site 451
Clermont-Ferrand
Research Site 458
Limoges
Research Site 456
Nîmes
Research Site 453
Paris
Research Site 457
Pringy
Research Site 452
Strasbourg
Research Site 454
Tours
Slovakia8 sites
Research Site 351
Banská Bystrica
Research Site 352
Bratislava
Research Site 353
Bratislava
Research Site 354
Bratislava
Research Site 356
Bratislava
Research Site 359
Dubnica nad Váhom
Research Site 358
Trenčín
Research Site 357
Trnava
Belarus5 sites
Research Site 143
Grodno
Research Site 144
Homyel
Research Site 142
Minsk
Research Site 141
Vitebsk
Research Site 145
Vitebsk
Malaysia5 sites
Research Site 551
Kuala Lumpur
Research Site 554
Kuala Lumpur
Research Site 556
Kuala Lumpur
Research Site 552
Kuching
Research Site 553
Seberang Jaya
Canada4 sites
Research Site 106
Burnaby
Research Site 107
London
Research Site 105
Montreal
Research Site 101
Ottawa
India4 sites
Research Site 445
Ahmedabad
Research Site 444
Bangalore
Research Site 443
Mangalore
Research Site 442
New Delhi
Lithuania4 sites
Research site 241
Kaunas
Research site 244
Klaipėda
Research site 243
Šiauliai
Research site 242
Vilnius
Romania4 sites
Research Site 314
Brasov
Research Site 307
Bucharest
Research Site 309
Caracal
Research Site 302
Târgu Mureş
South Africa4 sites
Research Site 501
Cape Town
Research Site 502
Cape Town
Research Site 503
Cape Town
Research Site 504
Pretoria
Sweden4 sites
Research Site 512
Gothenburg
Research site 514
Malmö
Research Site 511
Stockholm
Research Site 513
Uppsala
Latvia3 sites
Research Site 231
Riga
Research Site 232
Riga
Research Site 233
Riga
Norway3 sites
Research Site 481
Bergen
Research site 483
Drammen
Research Site 482
Namsos
Slovenia3 sites
Research Site 373
Celje
Research Site 372
Ljubljana
Research Site 371
Maribor
Switzerland3 sites
Research Site 404
Aarau
Research Site 402
Bern
Research Site 403
Lugano
Philippines2 sites
Research Site 562
Baguio City
Research Site 561
Cebu City
About this study
Official title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
- Conditions
- Relapsing Multiple Sclerosis
- Being tested
- Teriflunomide, Evobrutinib
- Keywords
- Evobrutinib, Teriflunomide, Aubagio®, Relapsing Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TeriflunomideDrug
Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.
EvobrutinibDrug
Also called M2951
Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.
| Study group | Role | What they receive |
|---|---|---|
| Teriflunomide | Active comparator | Not described Receives: Drug: Teriflunomide |
| Evobrutinib | Experimental | Not described Receives: Drug: Evobrutinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than [>] 24 hours, no fever, infection, injury, adverse events (AEs), and preceded by a stable or improving neurological state for more than or equal to [>=] 30 days).
Measured: Baseline up to 170 weeks
Secondary outcomes (31)
DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Disability progression was defined as increase in EDSS of greater than or equal to [>=] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of >=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.
Measured: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Disability progression was defined as increase in EDSS of greater than or equal to [>=] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of >=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.
Measured: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is >= 2 and less than or equal to [<=] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is >= 6.5 and <= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.
Measured: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156
Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).
Measured: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (Combined DBTP and DBE periods)
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156
PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).
Measured: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 ((combined DBTP and DBE periods)
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.
Measured: Baseline up to 170 weeks
DBTP and DBE Period: New or Enlarging T2 Lesions Rate
Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.
Measured: Baseline up to 170 weeks
DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12
NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.
Measured: Week 12
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)
Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight
Changes in vital signs: weight from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: heart rate from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration
QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 170 weeks were reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 170 weeks were reported. The Glomerular Filtration Rate was measured as milliliter per minute per 1.73 square meter (mL/min/1.73m^2).
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine
Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine
Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 170 weeks was reported.
Measured: Baseline up to 170 weeks
DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
Measured: At Week 170
DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels
Change from baseline serum levels of IgG, IgA, IgM were assessed.
Measured: Baseline up to 170 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2020
- Study start2 Jul 2020
- Primary completion2 Oct 2023
- Study completion19 Mar 2024
Why it stopped: Primary analysis of the RMS phase 3 study (MS200527\_0082) resulted in the early termination of the study.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Relapsing Multiple SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,166 participants (actual)
Sponsor and investigators
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- EMD Serono Research & Development Institute, Inc.
- Responsible party
- Sponsor
- Investigators
- Medical Responsible, Study director, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04338061
- Sponsor's protocol ID
- MS200527_0082
- Other IDs
- 2019-004980-36, 2019
- Status last verified
- Mar 2025
- First submitted
- 6 Apr 2020
- Last updated
- 21 Mar 2025
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Publications
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19.
PubMed 39307151
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)
- ClinicalTrials.gov ID
- NCT04338061
- Acronym / sponsor ID
- MS200527_0082
- Conditions
- Relapsing Multiple Sclerosis
- Keywords
- Evobrutinib, Teriflunomide, Aubagio®, Relapsing Multiple Sclerosis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Primary analysis of the RMS phase 3 study (MS200527\_0082) resulted in the early termination of the study.
- Enrolment
- 1,166 participants (actual)
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry (pharma, biotech, devices)
- Collaborators
- EMD Serono Research & Development Institute, Inc.
- Study start
- 2 Jul 2020 (actual)
- Primary completion
- 2 Oct 2023 (actual)
- Study completion
- 19 Mar 2024 (actual)
- First posted
- 8 Apr 2020 (actual)
- Results
- Posted 14 Jan 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Teriflunomide | Active comparator | Drug: Teriflunomide |
| Evobrutinib | Experimental | Drug: Evobrutinib |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
- Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
- Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score less than or equal to [<=] 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
- Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
- Female participants must be neither pregnant nor breast-feeding or must lack child-bearing potential (as defined by either: post-menopausal or surgically sterile), or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
Key exclusion criteria (4 listed)
- Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b) Participants with secondary progressive MS without evidence of relapse
- Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at screening and Baseline (Day 1)
- Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV), intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
- Other protocol defined exclusion criteria could apply.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TeriflunomideParticipants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period. | Drug | Teriflunomide |
| EvobrutinibAlso: M2951Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period. | Drug | Evobrutinib |
Primary outcome
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)
Time frame: Baseline up to 170 weeks
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than [>] 24 hours, no fever, infection, injury, adverse events (AEs), and preceded by a stable or improving neurological state for more than or equal to [>=] 30 days).
31 secondary outcomes
DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156
Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (Combined DBTP and DBE periods)
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156
Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 ((combined DBTP and DBE periods)
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions
Time frame: Baseline up to 170 weeks
DBTP and DBE Period: New or Enlarging T2 Lesions Rate
Time frame: Baseline up to 170 weeks
DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12
Time frame: Week 12
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine
Time frame: Baseline up to 170 weeks
DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels
Time frame: At Week 170
DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels
Time frame: Baseline up to 170 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Results publication: PubMed 39307151Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19.
- Trial Awareness and Transparency websiteLink provided by the sponsor.
- US Medical Information website, Medical ResourcesLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Related trials for Relapsing Multiple Sclerosis
Active, not recruiting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
Not yet recruitingPhase 1
A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Active, not recruitingObservational study
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Multiple Sclerosis
Recruiting
Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
Multiple Sclerosis (MS) - Relapsing-remitting, Upper Extremity Dysfunction
Not yet recruiting
Treatment of Memory Retrieval Impairments in MS With HDtDCS to the LIFG in a Placebo Controlled Trial
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Medical Responsible study director
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
278 sites in 32 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Teriflunomide and Evobrutinib in people with Relapsing Multiple Sclerosis, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany at 278 sites in 32 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 21 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 278 sites in United States, Russia, Ukraine, Poland, Bulgaria and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 14 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR) (time frame: Baseline up to 170 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04338061, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2025.